AIM: To investigate the possible association between meat intake, cigarette smoking and N-acetyltransferase 2 (NAT2) genetic polymorphisms on colorectal cancer (CRC) risk. METHODS: Patients with CRC were matched for gender and age to healthy controls. Meat intake and cigarette smoking were assessed using a specific frequency questionnaire. DNA was extracted from peripheral blood and the genotypes of the polymorphism were assessed by polymerase chain reaction-restriction fragment length polymorphism. Five NAT2 alleles were studied (WT, M1, M2, M3 and M4) using specific digestion enzymes. RESULTS: A total of 147 patients with colorectal cancer (76 women and 90 men with colon cancer) and 212 controls were studied. The mean age of the two groups was 62 years. More than half the subjects (59.8% in the case group and 51.9% in the control group) were NAT2 slow acetylators. The odds ratio for colorectal cancer was 1.38 (95% CI: 0.90-2.12) in slow acetylators. Although the number of women was small (n = 76 in the case group), the cancer risk was found to be lower in intermediate (W/Mx) acetylators [odds ratio (OR): 0.55, 95% confidence interval (95% CI): 0.29-1.02]. This difference was not observed in men (OR: 0.56, 95% CI: 0.16-2.00). Among NAT2 fast acetylators (W/W or W/Mx), meat consumption more than 3 times a week increased the risk of colorectal cancer (OR: 2.05, 95% CI: 1.01-4.16). In contrast, cigarette smoking increased the risk of CRC among slow acetylators (OR: 1.97, 95% CI: 1.02-3.79). CONCLUSION: The risk of CRC was higher among fast acetylators who reported a higher meat intake. Slow NAT2 acetylation was associated with an increased risk of CRC.
AIM: To investigate the possible association between meat intake, cigarette smoking and N-acetyltransferase 2 (NAT2) genetic polymorphisms on colorectal cancer (CRC) risk. METHODS:Patients with CRC were matched for gender and age to healthy controls. Meat intake and cigarette smoking were assessed using a specific frequency questionnaire. DNA was extracted from peripheral blood and the genotypes of the polymorphism were assessed by polymerase chain reaction-restriction fragment length polymorphism. Five NAT2 alleles were studied (WT, M1, M2, M3 and M4) using specific digestion enzymes. RESULTS: A total of 147 patients with colorectal cancer (76 women and 90 men with colon cancer) and 212 controls were studied. The mean age of the two groups was 62 years. More than half the subjects (59.8% in the case group and 51.9% in the control group) were NAT2 slow acetylators. The odds ratio for colorectal cancer was 1.38 (95% CI: 0.90-2.12) in slow acetylators. Although the number of women was small (n = 76 in the case group), the cancer risk was found to be lower in intermediate (W/Mx) acetylators [odds ratio (OR): 0.55, 95% confidence interval (95% CI): 0.29-1.02]. This difference was not observed in men (OR: 0.56, 95% CI: 0.16-2.00). Among NAT2 fast acetylators (W/W or W/Mx), meat consumption more than 3 times a week increased the risk of colorectal cancer (OR: 2.05, 95% CI: 1.01-4.16). In contrast, cigarette smoking increased the risk of CRC among slow acetylators (OR: 1.97, 95% CI: 1.02-3.79). CONCLUSION: The risk of CRC was higher among fast acetylators who reported a higher meat intake. Slow NAT2 acetylation was associated with an increased risk of CRC.
Authors: D W Hein; M A Doll; A J Fretland; M A Leff; S J Webb; G H Xiao; U S Devanaboyina; N A Nangju; Y Feng Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-01 Impact factor: 4.254
Authors: S Garte; L Gaspari; A K Alexandrie; C Ambrosone; H Autrup; J L Autrup; H Baranova; L Bathum; S Benhamou; P Boffetta; C Bouchardy; K Breskvar; J Brockmoller; I Cascorbi; M L Clapper; C Coutelle; A Daly; M Dell'Omo; V Dolzan; C M Dresler; A Fryer; A Haugen; D W Hein; A Hildesheim; A Hirvonen; L L Hsieh; M Ingelman-Sundberg; I Kalina; D Kang; M Kihara; C Kiyohara; P Kremers; P Lazarus; L Le Marchand; M C Lechner; E M van Lieshout; S London; J J Manni; C M Maugard; S Morita; V Nazar-Stewart; K Noda; Y Oda; F F Parl; R Pastorelli; I Persson; W H Peters; A Rannug; T Rebbeck; A Risch; L Roelandt; M Romkes; D Ryberg; J Salagovic; B Schoket; J Seidegard; P G Shields; E Sim; D Sinnet; R C Strange; I Stücker; H Sugimura; J To-Figueras; P Vineis; M C Yu; E Taioli Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-12 Impact factor: 4.254
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Ashwin N Ananthakrishnan; Mengmeng Du; Sonja I Berndt; Hermann Brenner; Bette J Caan; Graham Casey; Jenny Chang-Claude; David Duggan; Charles S Fuchs; Steven Gallinger; Edward L Giovannucci; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Lifang Hou; Li Hsu; Mark A Jenkins; Peter Kraft; Jing Ma; Hongmei Nan; Polly A Newcomb; Shuji Ogino; John D Potter; Daniela Seminara; Martha L Slattery; Mark Thornquist; Emily White; Kana Wu; Ulrike Peters; Andrew T Chan Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-23 Impact factor: 4.254
Authors: Lou qian Zhang; Jian nong Zhou; Jun Wang; Guo dong Liang; Jing ying Li; Yi dan Zhu; Yun tao Su Journal: PLoS One Date: 2012-03-05 Impact factor: 3.240